Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Net Income towards Common Stockholders fell 4508.89% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Net Income towards Common Stockholders stood at -$38.3 million, which was down 4508.89% from -$23.5 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Net Income towards Common Stockholders peaked at $112.9 million during Q1 2025, and registered a low of -$38.3 million during Q3 2025.
  • For the 4-year period, Stoke Therapeutics' Net Income towards Common Stockholders averaged around -$16.3 million, with its median value being -$25.7 million (2024).
  • Examining YoY changes over the last 5 years, Stoke Therapeutics' Net Income towards Common Stockholders showed a top increase of 52799.35% in 2025 and a maximum decrease of 4508.89% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Net Income towards Common Stockholders stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 258.95% to -$38.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$38.3 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $112.9 million in Q1 2025.